Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial

BACKGROUND: Two cycles of neoadjuvant PD-1 blockade plus chemotherapy induced favorable pathological response and tolerant toxicity in patients with locally advanced esophageal squamous cell carcinoma (ESCC). However, approximately 25% of patients relapsed within 1 year after surgery, indicating tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Guozhen, Su, Xiaodong, Huang, Yuanheng, Luo, Guangyu, Wang, Zhiqiang, Cai, Peiqiang, Zheng, Yating, Bei, Ting, Huang, Mengli, Bai, Yuezong, He, Haoqiang, Xiang, Jin, Cai, Muyan, Zhong, Jiudi, Guo, Qiyu, Zhang, Xu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290378/
https://www.ncbi.nlm.nih.gov/pubmed/37355621
http://dx.doi.org/10.1186/s12967-023-04273-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290378/
https://www.ncbi.nlm.nih.gov/pubmed/37355621
http://dx.doi.org/10.1186/s12967-023-04273-6

Ejemplares similares